Cart
sales@molnova.com
Mutant IDH1 inhibitor
CAS No. 1429180-08-4
Mutant IDH1 inhibitor( —— )
Catalog No. M23590 CAS No. 1429180-08-4
Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 151 | In Stock |
|
| 10MG | 259 | In Stock |
|
| 25MG | 437 | In Stock |
|
| 50MG | 624 | In Stock |
|
| 100MG | 888 | In Stock |
|
| 500MG | 1773 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMutant IDH1 inhibitor
-
NoteResearch use only, not for human use.
-
Brief DescriptionMutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).
-
DescriptionMutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
Recptormutant IDH1 R132H
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1429180-08-4
-
Formula Weight466.6
-
Molecular FormulaC25H34N6O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:30 mg/mL (64.3 mM)
-
SMILESCC(C)[C@@H](COC1=O)N1c1nc(N[C@@H](C)c2ccc(CN(CC3)CCN3C(C)=O)cc2)ncc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH and their preparation. Patent WO 2013046136 A1 20130404
molnova catalog
related products
-
Galloflavin
Galloflavin inhibits both the A and B isoforms of lactate dehydrogenase with Ki of 5.46 μM and 15.06 μM, respectively.
-
IDH889
IDH889 is a brain penetrant, an allosteric and mutant specific IDH1 inhibitor. IDH889 has effective selectivity for IDH1 R132* mutations (IC50s: 0.02 μM, 0.072 μM, and 1.38 μM for IDH1R132H, IDH1R132C, and IDH1wt).
-
PfDHODH-IN-1
PfDHODH-IN-1 is an inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase(PfDHODH) which catalyzes the rate-limiting step for DNA and RNA biosynthesis. PfDHODH-IN-1 has antimalarial activity.
